G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020
G1 Therapeutics (GTHX) has announced a webcast and conference call scheduled for August 5, 2020, at 5:00 p.m. ET, to provide a corporate and financial update for Q2 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics (GTHX) has announced a webcast and conference call scheduled for August 5, 2020, at 5:00 p.m. ET, to provide a corporate and financial update for Q2 2020. Investors can participate by calling 866-763-6020 (domestic) or 210-874-7713 (international), using conference code 4648036. The event will be accessible via the company's website.
G1 is focused on developing innovative cancer therapies including Trilaciclib, a Breakthrough Therapy, Rintodestrant, an oral SERD, and Lerociclib, a CDK4/6 inhibitor.
Positive
- Scheduled Q2 2020 corporate and financial update, indicating ongoing engagement with investors.
- Presence of innovative therapies in the pipeline, including FDA-designated Breakthrough Therapy.
Negative
- None.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -2.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00 p.m. ET.
The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 4648036. The live and archived webcast will be available on the Events & Presentations page of the G1 website.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.